Administering

Off-label or unlicensed product use under HMR 2012 exemptions

8 January 2020The below summary details the legal position regarding the sale, supply or administration of off-label/unlicensed products under Schedule 17 of the HMR 2012

Patient Group Direction use in End of Life Care

10 August 2020Considerations required before implementing Patient Group Direction (PGDs) for in End of Life Care

Using intravenous paracetamol preparations safely in paediatrics

21 September 2022Safety risks and mitigation strategies are described to reduce the risk of errors with intravenous paracetamol in neonates, infants, and children.

Treating acute hypokalaemia in adults

14 August 2024

Administration of contrast agents under a PGD by multiple HCPs

15 July 2024

Acute settings and transcribing

22 February 2022Consideration needs to be given to the risk factors particularly associated with transcribing in acute settings

Transcribing in the patient's home with healthcare input

22 February 2022Consideration needs to be given to the risk factors particularly associated with transcribing in the patient's home with healthcare input

Worked example of assessing the risk of transcribing

22 February 2022Example where medicines are prescribed by both the patient’s GP and specialist clinicians, and are administered in a patient’s home.

Implementing self-administration of medicines

25 January 2023Patients under hospital care should be supported to continue self-administering unless there are good reasons why they are unable to

Using solid oral dosage form antibiotics in children

7 December 2022Crushing or dispersing whole solid dosage forms or opening capsules is an "off-label" use. This includes use for Group A streptococcal infections.

SPS - Specialist Pharmacy Service

NHS